Holds one active US DMF for ambrisentan, filing since 2012. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for ambrisentan, filing since 2015. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds one active US DMF for ambrisentan, filing since 2015. Its 2023 FDA inspection closed as VAI.
Holds one active US DMF for ambrisentan, filing since 2010. Its 2025 FDA inspection closed as VAI.
Holds one active US DMF for ambrisentan, filing since 2016. Its 2024 FDA inspection closed as VAI.
Holds one active US DMF for ambrisentan, filing since 2014. Its 2018 FDA inspection closed as VAI.
Holds one active US DMF for ambrisentan, filing since 2016.
Holds one active US DMF for ambrisentan, filing since 2013. Its 2025 FDA inspection closed as OAI, and its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free